Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
Vukusic S, Marignier R, Ciron J, Bourre B, Cohen M, Deschamps R, Guillaume M, Kremer L, Pique J, Carra-Dalliere C, Michel L, Leray E, Guennoc AM, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Daval E, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Hebant B, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Roux T, Maillart E, Lebrun-Frenay C. Vukusic S, et al. Among authors: bigaut k. Mult Scler. 2023 Jan;29(1):37-51. doi: 10.1177/13524585221130934. Epub 2022 Nov 8. Mult Scler. 2023. PMID: 36345839 Review.
Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
Bigaut K, Lambert C, Kremer L, Lebrun C, Cohen M, Ciron J, Bourre B, Créange A, Kerschen P, Montcuquet A, Carra-Dalliere C, Ayrignac X, Labauge P, de Seze J, Collongues N. Bigaut K, et al. Mult Scler. 2021 Feb;27(2):232-238. doi: 10.1177/1352458520906995. Epub 2020 Feb 20. Mult Scler. 2021. PMID: 32077365
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, Deschamps R, Créange A, Wahab A, Pelletier J, Heinzlef O, Labauge P, Guilloton L, Ahle G, Goudot M, Bigaut K, Laplaud DA, Vukusic S, Lubetzki C, De Sèze J; Covisep investigators; Derouiche F, Tourbah A, Mathey G, Théaudin M, Sellal F, Dugay MH, Zéphir H, Vermersch P, Durand-Dubief F, Françoise R, Androdias-Condemine G, Pique J, Codjia P, Tilikete C, Marcaud V, Lebrun-Frenay C, Cohen M, Ungureanu A, Maillart E, Beigneux Y, Roux T, Corvol JC, Bordet A, Mathieu Y, Le Breton F, Boulos DD, Gout O, Guéguen A, Moulignier A, Boudot M, Chardain A, Coulette S, Manchon E, Ayache SS, Moreau T, Garcia PY, Kumaran D, Castelnovo G, Thouvenot E, Taithe F, Poupart J, Kwiatkowski A, Defer G, Derache N, Branger P, Biotti D, Ciron J, Clerc C, Vaillant M, Magy L, Montcuquet A, Kerschen P, Coustans M, Guennoc AM, Brochet B, Ouallet JC, Ruet A, Dulau C, Wiertlewski S, Berger E, Buch D, Bourre B, Pallix-Guiot M, Maurousset A, Audoin B, Rico A, Maarouf A, Edan G, Papassin J, Videt D. Louapre C, et al. Among authors: bigaut k. JAMA Neurol. 2020 Sep 1;77(9):1079-1088. doi: 10.1001/jamaneurol.2020.2581. JAMA Neurol. 2020. PMID: 32589189 Free PMC article.
Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
Bigaut K, Fabacher T, Kremer L, Ongagna JC, Kwiatkowski A, Sellal F, Ferriby D, Courtois S, Vermersch P, Collongues N, Zéphir H, De Seze J, Outteryck O. Bigaut K, et al. Mult Scler. 2021 Apr;27(5):729-741. doi: 10.1177/1352458520936239. Epub 2020 Jul 9. Mult Scler. 2021. PMID: 32643521
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Wiertlewski S, Brochet B, Ruet A, Defer G, Derache N, Vermersch P, Zephir H, Debouverie M, Mathey G, Berger E, Cappé C, Labauge P, Carra C, De Seze J, Bigaut K, Brassat D, Lebrun-Frenay C. Cohen M, et al. Among authors: bigaut k. Mult Scler. 2021 Sep;27(10):1556-1563. doi: 10.1177/1352458520969145. Epub 2020 Oct 30. Mult Scler. 2021. PMID: 33124504
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
Bigaut K, Cohen M, Durand-Dubief F, Maillart E, Planque E, Zephir H, Lebrun-Frenay C, de Seze J; French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Française de la Sclérose En Plaques (SFSEP). Bigaut K, et al. Mult Scler Relat Disord. 2021 Aug;53:103076. doi: 10.1016/j.msard.2021.103076. Epub 2021 Jun 10. Mult Scler Relat Disord. 2021. PMID: 34161898
43 results